Black Diamond Therapeutics, Inc. 8-K

What Happened

• Black Diamond Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026 in a press release dated May 7, 2026. The company furnished the press release as Exhibit 99.1 to the Current Report on Form 8‑K filed May 7, 2026. The Form 8‑K was signed by Brent Hatzis‑Schoch, Chief Operating Officer and General Counsel.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (quarter ended March 31, 2026).
• Exhibit: 99.1 — Press release dated May 7, 2026 announcing the results.
• Legal note: The information in this Form 8‑K (including Exhibit 99.1) is furnished, not “filed,” under the Exchange Act and therefore is not subject to Section 18 liability or automatically incorporated by reference in other filings.
• Form signed by Brent Hatzis‑Schoch on May 7, 2026.

Why It Matters

• This 8‑K notifies investors that Black Diamond has released its quarterly results; investors should review Exhibit 99.1 (the press release) for the detailed financial metrics (revenue, net income/loss, cash position) and any operational or development updates.
• The “furnished, not filed” status limits certain legal liabilities and means the press release is provided for information but is not treated as a filed SEC disclosure for Section 18 purposes.